Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 421 participants.
Also called NCT01456195
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 421 participants
- Sponsor
- Registry
-
NCT01456195 -
2011-002741-35 -
U1111-1124-2154
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Bulgaria, Guatemala, Hungary, Mexico, Slovakia, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01456195. Randomized; quadruple masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-07 (actual). Results posted on 2016-04-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Fasiglifam
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct01456195- Content hash
37e7c755cee59c4623f5d619eb53b07a99c328b2eb7d6b7f9d7f53b9363986c1